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Abstract: A new alkaloid paenidigyamycin A (1) was obtained from the novel Ghanaian Paenibacillus sp.
isolated from the mangrove rhizosphere soils of the Pterocarpus santalinoides tree growing in the
wetlands of the Digya National Park, Ghana. Compound 1 was isolated on HPLC at tR = 37.0 min and
its structure determined by MS, 1D, and 2D-NMR data. When tested against L. major, 1 (IC50 0.75 µM)
was just as effective as amphotericin B (IC50 0.31 µM). Against L. donovani, 1 (IC50 7.02 µM) was
twenty-two times less active than amphotericin B (IC50 0.32 µM), reinforcing the unique effectiveness
of 1 against L. major. For T. brucei brucei, 1 (IC50 0.78 µM) was ten times more active than the
laboratory standard Coptis japonica (IC50 8.20 µM). The IC50 of 9.08 µM for 1 against P. falciparum 3d7
compared to artesunate (IC50 36 nM) was not strong, but this result suggests the possibility of using
the paenidigyamycin scaffold for the development of potent antimalarial drugs. Against cercariae,
1 showed high anticercaricidal activity compared to artesunate. The minimal lethal concentration
(MLC) and minimal effective concentration (MEC) of the compound were 25 and 6.25 µM, respectively,
while artesunate was needed in higher quantities to produce such results. However, 1 (IC50 > 100 µM)
was not active against T. mobilensis.
Keywords: paenidigyamycin; plasmodium; trypanosome; leishmania; trichomonas; schistosome
1. Introduction
Sub-Sahara Africa (SSA) is burdened with a high incidence of parasitic infections, including
schistosomiasis, trypanosomiasis, trichomoniasis, and leishmaniasis [1–3]. Currently, there is a rapid
widespread development of resistance to prescription drugs for these parasitic neglected tropical
diseases (pNTDs) [4–8]. The available number of drugs for treatment is exceptionally low and each
of these has been under prescription for periods of no less than 30 years [9]. A rough estimate of
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the average of the prescription periods from time of discovery to-date for the top 10 antiparasitics,
including praziquantel or oxamniquine, amphotericine, pentavalent antimonials, paromomycin,
miltefosine, pentamidine, fluconazole or itraconazole, melarsoprol, eflornithine, and nifurtimox
that are currently prescribed in the clinic is about 56 years. Furthermore, pNTD drugs only treat
specific stages of parasite development, thereby complicating the treatment routines for patients and
preventing complete parasite removal from the body [10,11]. Due to their long time prevalence in
SSA, pNTDs have parasites and vectors whose genomes and lifecycles have evolved to assure their
resilience and persistence [4]. Vectors responsible for pNTD transmissions are difficult to control
and there is a huge debate concerning attempts to completely annihilate them [12]. Clearly, there is
an urgent need to discover new scaffolds that would provide a platform for the development of
future antiparasitics against pNTDs [13]. Microbial natural products provide the largest chemical
and biological diversity in any drug discovery screening program compared to other natural
sources, like plants and invertebrates, with the resupply problems mostly overcome with large-scale
fermentation and heterologous expression [9,14–16]. Extreme un- or underexplored environments
in SSA harbor novel microbes which, through millions of years of evolution, have evolved genomes
that express chemically diverse molecules that could act as future drug leads for pNTDs and other
diseases [17,18].
In the last four years, we have collected several soils and sediments from unexplored unique
environments in the Ghanaian Western, Volta, and Brong Ahafo Regional wetlands. From these
samples, we have isolated many cultivable strains of microbes, most of which give extracts which
show antiparasitic activity.
Herein, we report on the isolation and purification of the Ghanaian Paenibacillus sp. strain DE2SH
(GenBank Accession Number: MH091697) from mangrove rhizosphere soils collected from the Digya
National Park in the Brong Ahafo Regional wetlands of Ghana. Culture of this strain at 28 ◦C, 220 rpm,
in ISP2 media at pH 5.5 produced a crude extract which possessed antiparasitic activity against
trypanosomes, schistosomes, leishmania, and plasmodium. Chemical profiling of this extract using
high resolution electrospray ionization liquid chromatography mass spectrometry (HRESI-LC-MS)
and nuclear magnetic resonance spectroscopy (NMR) showed the presence of an alkaloid which
we have named paenidigyamycin (Figure 1). Solvent partitioning, Sephadex LH-20 size exclusion
chromatography, and HPLC yielded the potent antiparasitic, paenidigyamycin A (1) (1.6 mg/L).
The structure of this compound was determined using a combination of 1D- and 2D-NMR techniques
with HRESI-LC-MS data.
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Figure 1. Structure of the imidazole-based alkaloid paenidigyamycin A (1) isolated from Paenibacillus 
sp. DE2SH. 
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Figure 1. Structure of the imidazole-based alkaloid paenidigyamycin A (1) isolated from Paenibacillus sp. DE2SH.
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2. Results and Discussion
2.1. Sediment Sample Collection Sites
The Ghanaian Paenibacillus sp. strain DE2SH (Supplementary Figure S1) was isolated from the
mangrove rhizosphere soils of the Pterocarpus santalinoides tree growing in the wetland areas of the
Digya National Park in the Brong Ahafo Region of Ghana (coordinates: 7◦12′17.46”N and 0◦05′35.01”E).
This area has several patches of mangroves which are associated with the biggest reservoir man-made
lake, Lake Volta. Water from the tributaries of the Volta ensures that the area occupied by this tree is
covered with water throughout the year. Lake Volta is an open lake that is connected to the sea at the
Ada Foah Basin, which in itself is a very dramatic site. The lake water is appreciably saline because,
at high tide, seawater is pumped into the lake. Therefore, the diversity of micro- and macro-flora and
fauna species is very high compared to lakes that have no connections with the sea. Several organisms
that are meant to be entirely marine can be found in the lake and that includes marine microbes and
fish [19]. There are a lot of species mixing in the mangroves associated with the lake, all the way to the
Digya National Park.
2.2. Taxonomy of Strain DE2SH
Identification of phylogenetic neighbors and calculation of pairwise 16S rRNA gene sequence
similarities were achieved using the EzTaxon-e server [20]. Phylogenetic analysis was performed with
the software package MEGA v.7.0 [21] after multiple sequence alignments with CLUSTAL W [22].
Distances were calculated according to the methods of Jukes-Cantor [23]. Phylogenetic trees were
inferred using the neighbour-joining [24], maximum-parsimony [25], and maximum-likelihood [26]
methods. The resultant tree topologies were evaluated by bootstrap analyses [27] based on
1000 re-samplings of the datasets. The comparative analysis of the 16S rRNA gene sequence of
strain DE2SH revealed that it was phylogenetically affiliated to the genus Paenibacillus (Figure 2).
Paenibacillus sp. strain DE2SH had the highest 16S rRNA gene sequence similarities with the type
strains P. jamilae (99.11%), P. polymyxa (98.85%), P. peoriaea (98.84%), and P. brasilensis (98.70%), and
other species of the genus Paenibacillus (<98.10%).
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Figure 2. Neighbour-joining phylogenetic tree based on 16S rR gene sequences showing the
relationships between strain DE2SH and other representative members of species of the genus
Paenibacillus. Bacillus subtilis AJ276351T was used as an out-group. Asterisks (*) indicate branches that
were also found using the maximum-parsimony [28] and maximum-likelihood methods [26]. Numbers
at branch points indicate bootstrap percentages (based on 1000 replicates); only values >50% indicated.
Bar, 0.01 substitutions per nucleotide position.
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2.3. Structure Determination of Paenidigyamycin A (1)
Compound 1 was obtained at tR of 37.0 min on semi-preparative reverse phase HPLC. It is
a colorless and odorless oil when completely free of solvent. The HRESI-LC-MS of compound 1 gave
an m/z of 271.2162, corresponding to a molecular formula of C18H27N2 (∆ = 0.001 and 7 degrees
of unsaturation). It appears that compound 1 easily fragments in the mass spectrometer to yield
two fragments with the same m/z of 271.2162 (Supplementary Figures S2–S4). Therefore, the m/z of 1
was calculated as 540.4186, which corresponds to the molecular formula of C36H52N4 with 14 degrees
of unsaturation. Analysis of the 1H, 13C, and multiplicity edited gHSQCAD spectra of 1, suggested the
presence of 8 quaternary, 12 methine, 8 methylene, and 8 methyl carbons. The 1H-NMR chemical shifts
δH 7.10 (4H, m, H-2′, H-2”, H-6′, H-6”), 7.31 (4H, m, H-3′, H-3”, H-5′, H-5”), and 7.29 (2H, m, H-4′, H-4”)
provided direct evidence for the presence of two mono-substituted benzene rings. Mono-substituted
benzene rings have a well-known reputation of producing weakly resolved multiplicity patterns due to
the identical coupling constants which exist in such systems. Detailed analysis of the gCOSY spectrum
showed correlations H-2′/H-3′, H-2”/H-3”, H-5′/H-6′, and H-5”/H-6”, which were further supported
by similar 2D-TOCSY correlations, including H-2′/H-4′, H-6′/H-4′, H-2”/H-4”, and H-6”/H-4” to fully
establish these aromatic spin systems. Important gHMBCAD correlations, such as C-1′ to H-3′, C-1′
to H-5′, C-1” to H-3”, and C-1” to H-5”, confirmed that the only quaternary carbon outlet within the
aromatic systems was δC 137.8 (C-1′ and C-1”). Most importantly, gHMBCAD correlations C-1′ to H-8,
C-1” to H-8′, C-1′ to H-9, and C-1” to H-9′ showed that the two aromatic systems were both attached
to an ethyl group with carbon atoms at δC 49.7 (C-8), 36.7 (C-9), 49.2 (C-8′), and 37.1 (C-9′), and δH 4.40
(2H, t, J = 6.8 Hz, H-8), 3.12 (2H, t, J = 6.7 Hz, H-9), 4.33 (2H, t, J = 6.9 Hz, H-8′), and 3.04 (2H, t, J = 6.9 Hz,
H-9′), respectively. The gCOSY correlations H-8/H-9 and H-8′/H-9′ confirmed these two isolated
spin systems with the lower methylene chemical shift carbons δC 36.7 (C-9) and 37.1 (C-9′) attached
to the mono-substituted benzene rings, while the higher methylene chemical shift carbons δC 49.7
(C-8) and 49.2 (C-8′) were attached to the nitrogen of possible heteroaromatic systems. Furthermore,
two isopentyl spin systems were identified with δH 4.03 (2H, m, H-10), 1.57 (2H, m, H-11), 1.48 (1H, n,
J = 6.8 Hz, H-12), 0.96 (6H, d, J = 6.6 Hz, H-13, H-14) and 4.13 (2H, m, H-10′), 1.73 (2H, m, H-11′), 1.67
(1H, n, J = 6.8 Hz, H-12′), and 1.02 (6H, d, J = 6.5 Hz, H-13′, H-14′). The δH 4.03 (2H, m, H-10) and 4.13
(2H, m, H-10′) with δC 46.4 (C-10) and 46.6 (C-10′) were obviously connected to the nitrogen of some
heteroaromatic systems. With two ethyl benzenes and two isopentyl substructures completely solved,
the presence of the imidazole moiety was deduced by the subtraction of the known molecular formulas
from the overall formula and the subsequent calculation of unsaturation numbers. The presence of the
two imidazole rings was further confirmed by the rather low δC 8.1 (C-6), 8.1 (C-7) and δC 8.2 (C-6′), 8.0
(C-7′), which is very characteristic of methyl carbons attached to imidazole. The six imidazole δC 135.4
(C-2), 135.5 (C-2′), 128.4 (C-4), 128.5 (C-4′), 128.4 (C-5), and 128.5 (C-5′) were identified with gHMBCAD
correlations C-4 to H-6, H-10, C-5 to H-7, H-8 and C-4′ to H-6′, H-10′, C-5′ to H-7′, and H-8′, confirming
the positions of the methyl substituents on the imidazole ring, as well as the pattern of substitution
of the isopentyl and ethyl benzene moieties on the nitrogen of the imidazole rings. The structure of
paenidigyamycin A was further confirmed by the analysis of NOESY data, which along with the other
2D-NMR data, are summarized in Figures 3 and 4 and Table 1. The full details of all the NMR data
with correlations can be found in the Supplementary Table S1a,b, but the summary is shown in Table 1.
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Table 1. 1D and HMBC NMR Spectroscopic Data for Paenidigyamycin A (1) in CD3OD, in ppm.
# δC mult δH mult (J Hz) HMBC # δC mult δH mult (J Hz) HMBC
1-N 1′-N
2 135.4, C 8, 10 2′ 135.5, C 8′, 10′
3-N 3′-N
4 128.4, C 10, 6 4′ 128.5, C 10′, 6′
5 128.4, C 8, 7 5′ 128.5, C 8′, 7′
6 8.1, CH3 2.27, s 6′ 8.2, CH3 2.31, s
7 8.1, CH3 2.22, s 7′ 8.0, CH3 2.06, s
8 49.7, CH2 4.40, t (6.8) 9 8′ 49.2, CH2 4.33, t (6.9) 9′
9 36.7, CH2 3.12, t (6.7) 8, 2′, 6′ 9′ 37.1, CH2 3.04, t (6.9) 8′
10 46.4, CH2 4.03, m 12, 11 10′ 46.6, CH2 4.13, m 12′, 11′
11 39.5, CH2 1.57, m 13, 14, 10, 12 11′ 39.5, CH2 1.73, m 13′, 14′, 12′, 10′
12 26.5, CH 1.48, n (6.8) 13 14, 10 12′ 26.9, CH 1.67, n (6.8) 13′, 14′, 11′, 10′
13 22.5, CH3 0.96, d (6.6) 14 13′ 22.5, CH3 1.02, d (6.5) 14′
14 22.5, CH3 0.96, d (6.6) 13 14′ 22.5, CH3 1.02, d (6.5) 13′
1′ 137.8, C 9, 8, 3′, 5′ 1” 137.8, C 3”, 5”, 9′, 8′
2′ 130.0, CH 7.10, m 9, 4′, 3′, 5′ 2” 130.0, CH 7.10, m ”, 3”, 5”, 9′
3′ 130.0, 7.31, m 2′, 6′ 3” 130.0, CH 7.31, m 2”, 6”
4′ 1 8 4, 7.29, m 2′, 6′ ” 128.4, CH 7.29, m 2”, 6”
5′ 130.0, CH 7.31, m 2′, 6′ 5” 130.0, CH 7.31, m 2”, 6”,
6′ 130.0, CH 7.10, m 9, 4′, 3′, 5′ 6” 130.0, CH 7.10, m 4”, 3”, 5”, 9′
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2.4. Antiparasitic and Antibacterial Activity of Paenidigyamycin A
Compound 1 did not show any positive response when tested against a range of cancer cell
lines in our laboratory. These cancer cell lines include: Jurkat; Human T-lymphoblastic leukemia
and HL-60; Human promyelocytic leukemia cells, which are suspension cells; followed by PC-3;
Human Prostate Cancer, HepG2; Human hepatocellular carcinoma, LNCap; Human prostate cancer,
and MCF-7; Human breast cancer, which are adhesive cells. The antibacterial activity of 1 ranged from
moderate to weak when the compound was tested against Escherichia coli, Staphylococcus aureus, Bacillus
cereus, Shigella flexneri, Salmonella paratyphi B, and Listeria monocytogenes (Table 2). However, against
Plasmodium falciparum 3d7 strain, Trypanosoma brucei brucei, Leishmani donovani, and Leishmania major,
1 consistently produced very potent results (Table 3). Against L. major, compound 1 (IC50 0.75 µM) was
just as effective as the rather expensive and structurally complicated amphotericin B (IC50 0.31 µM).
Given the simplicity in the structure of 1, synthetic production of this compound could easily be
commercialized. Against L. donovani, compound 1 (IC50 7.02 µM) was twenty-two times less active
than amphotericin B (IC50 0.32 µM), but this result is interesting because it reinforces the unique
effectiveness of 1 against L. major. For T. brucei brucei, 1 (IC50 0.78 µM) was ten times more active
than the laboratory standard Coptis japonica (IC50 8.20 µM), which is reported to contain the alkaloid
berberine (Table 3). The IC50 of 9.08 µM for 1 against P. falciparum 3d7 strain compared to artesunate
(IC50 36 nM) is not strong, but this result suggests the possibility of using the paenidigyamycin scaffold
for the development of potent antiparasitic drugs.
Table 2. Antibacterial bioactivity data of compound 1 with ampicillin as the positive control.
Compound (1) Microbe IC50 (µM) Positive Control IC50 (µM)
Paenidigyamycin A
E. coli 76.98 Ampicillin 10.44
S. aureus 11.87 Ampicillin 0.18
B. cereus 97.23 Ampicillin 1.70
S. flexneri 56.98 Ampicillin 1.76
S. paratyphi B 57.98 Ampicillin 1.53
L. monocytogenes 18.98 Ampicillin 2.71
Table 3. Antiparasitic bioactivity data for compound 1.
Compound (1) Parasite IC50 (µM) Positive Control IC50
Paenidigyamycin A
P. falciparum 3d7 9.08 Artesunate 36 nm
T. brucei brucei 0.78 Coptis japonica 8.20 µM
L. donovani 7.02 Amphotericin B 0.32 µM
L. major 0.75 Amphotericin B 0.31 µM
Compound 1 showed varying anticercaricidal potency against Schistosoma mansoni cercariae,
with pronounced activity at elevated concentrations of the compound. The effect of incubation with
different concentrations of the compound on the viability of cercariae for up to 180 min is shown in
Supplementary Figure S5. The exposure of S. mansoni cercariae to compound 1 for 30, 60, 90, 120,
150, and 180 min showed a steady increase in the mortality rates of the parasite. In the absence
of the compound, cercariae showed normal viability, without any morphological changes (tail loss)
for up to 180 min. However, after incubation with the compound at the highest concentration of
100 µM, cercariae viability decreased significantly within 30 min, with complete mortality at 60 min.
At concentrations of 25–100 µM, cercariae viability decreased significantly within 60 min, with no
movement observed. At 90 min, cercariae incubated with 12.5 µM showed slowed movements and the
same was observed for 6.25 µM after 120 min. After 150 min and incubation with 25, 50, and 100 µM
concentrations of the compound, there was 100% mortality, with changes in viability and morphology
for 6.25 and 12.5 µM. The MLC and MEC of compound 1 on cercariae after 180 min were 25 µM and
6.25 µM, respectively. The standard artesunate which was chosen for these experiments as a result of
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its reported effectiveness against the juvenile forms of the schistosome worms was required in higher
concentrations to produce the same effects as compound 1 [29]. The LC50 for the different time points
for artesunate were calculated at 60 min (33.7 µM), 90 min (25.0 µM), 120 min (20.2 µM), 150 min
(16.44 µM), and 180 min (15.08 µM). These results suggest that the paenidigyamycin scaffold could
provide possible future antiparasitic drugs and it is our intention to investigate this compound further.
We hope to synthesize the compound and derivatives in order to determine and possibly compare the
antiparasitic activities.
However, when tested against Trichomonas mobilensis, compound 1 did not give any good
results (Table 4).
Table 4. In-vitro susceptibility results for Trichomonas mobilensis.
Compound (1) Parasite IC50 (µM) Positive Control IC50 (µM)
Paenidigyamycin A T. mobilensis > 100 Metronidazole 5.2
2.5. Possible Biosynthesis of Paenidigyamycin A (1)
Detailed inspection of the structure of paenidigyamycin A (1) led to the speculation that 1 could
be biosynthesized through the condensation of four units: diacetyl (2), 3-methylbutanamine (3),
2-phenyl-ethanamine (4), and formaldehyde (5). Diacetyl (2) is most likely derived from acetolactate
through non-enzymatic oxidative decarboxylation. The precursors 3 and 4 are also the decarboxylation
products of the corresponding amino acids leucine and phenylalanine, respectively. The cyclization
intermediate 6 will then undergo dehydration to yield 7, followed by tautomerization to yield 7′.
Finally, the dimerization occurs to provide 1, probably through a radical reaction between the
two monomers (Scheme 1).
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3. Experimental Section
3.1. General Experimental Procedures
1D and 2D NMR data were recorded on a Bruker AVANCE III HD Prodigy (BRUKER, Sylvenstein,
Germany) at 500 and 125 MHz for 1H and 13C, respectively. This instrument was optimized for 1H
observation with pulsing/decoupling of 13C and 15N, with 2H lock channels equipped with shielded
z-gradients and cooled preamplifiers for 1H and 13C. The 1H and 13C chemical shifts were referenced
to the solvent signals (δH 3.31 and δC 49.00 ppm in CD3OD). High-resolution mass spectrometry
data were measured using a ThermoScientific LTQXL-Discovery Orbitrap (Thermo Scientific, Bremen,
Germany) coupled to an Accela UPLC-DAD system. The following conditions were used for mass
spectrometric analysis: capillary voltage 45 V, capillary temperature 320 ◦C, auxiliary gas flow rate
10−20 arbitrary units, sheath gas flow rate 40−50 arbitrary units, spray voltage 4.5 kV, and mass range
100−2000 amu (maximum resolution 30,000). Semi-preparative HPLC purifications were carried out
using a Phenomenex Luna reverse-phase (C18 250 × 10 mm, L × i.d.) column connected to a Waters
1525 Binary HPLC pump Chromatograph with a 2998 photodiode array detector (PDA), column heater,
and in-line degasser. Detection was achieved on-line through a scan of wavelengths from 200 to
400 nm. This system was also used to record the UV profile for the compounds. IR was measured
using a PerkinElmer FT-IR (UATR Two) spectrometer. All solvents were HPLC grade. Sephadex LH-20
and HP-20 resin were obtained from Sigma Aldrich (Munich, Germany).
3.2. Identification of Strain DE2SH
Sanger and whole-genome sequencing of the strain was carried out by the DNA Sequencing
Facility, Department of Biochemistry, University of Cambridge. In this work, genomes were assembled
into a small number of high quality scaffolds by Dr. Markiyan Samborskyy using a combination of
shotgun and long-range mate pair Illumina sequencing data. A nearly complete sequence (1476 bp)
of the 16S rRNA gene obtained in the present study was used for the identification of isolated strain
DE2SH and for the construction of a phylogenetic tree. The 16S rRNA gene sequence was deposited in
the GenBank database (GenBank accession number: MH091697).
3.3. Fermentation
An Autoclaved Erlenmeyer flask (250 mL) plugged with non-absorbent cotton wool containing
50 mL of ISP2 (10 g of malt extract, 4 g each of yeast extract and D-glucose) fermentation media in
distilled water with pH 5.5 was directly inoculated with spores of strain DE2SH and incubated at 28 ◦C
at 220 rpm for three days. This seed culture was subsequently used to inoculate nine autoclaved 1 L
Erlenmeyer flasks, each containing 200 mL ISP2 media at pH 5.5 and plugged with non-absorbent
cotton wool. The 1 L flasks were incubated at 28 ◦C at 220 rpm for 21 days. Two days before the culture
incubation period was complete, autoclaved HP-20 resin was added at 50 g/L to each of the flasks
under sterile conditions and the flasks were returned to the incubator.
3.4. Extraction and Purification
The Paenibacillus sp. strain DE2SH fermentation broth (1.8 L) was filtered through a piece of glass
wool under suction in a Buchner funnel to separate the supernatant from the mycelia. The supernatant
was extracted with EtOAc and the mycelia and HP-20 resin were placed in a 1 L flask and extracted
sequentially and alternatively with MeOH and CH2Cl2. All extracts were combined and evaporated
under reduced pressure to obtain a total crude extract (2.84 g). The total crude extract was subjected to
a modification of Kupchan’s solvent partitioning process [30] that gave the four fractions FH (0.65 g),
FD (0.48 g), FM (0.32 g), and WB (1.08 g), with the compounds of interests concentrated in the
polar FM and WB fractions. The FM fraction was then subjected to Sephadex LH-20 size exclusion
chromatography by gravity to obtain six fractions that were labelled FM-SFA-F. Phytochemical
screening with ninhydrin on TLC plates followed by 1H-NMR showed the compound of interest to be
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concentrated in the FM-SFD (0.15 g). Fraction FM-SFD was therefore subjected to semi-preparative
HPLC separation and purification using a Phenomenex Luna C18 column (C18 250 × 10 mm, L × i.d.).
Gradients of Solvent A: H2O (0.1% HCOOH) and Solvent B: CH3CN (0.1% HCOOH) (100% A to 100%
B in 30 min and hold for 30 min) were used as eluents with column flow rates set at 1.5 mL/min to
afford compound 1 (1.2 mg, tR = 37.0 min).
Paenidigyamycin A (1): colorless and odorless substance; IR (neat) νmax 3088, 3064, 3028, 2962,
2930, 2872, 1661, 1516, 1496, 1374, 751, 703 cm−1; UV (H2O:CH3CN) λmax 210, 254, 280 nm; for 1H and
13C NMR data, see Table 1; Mass spectrometry data is detailed in Supplementary Figures S2–S4.
3.5. Bioassay Reagents
Fetal Bovine Serum (FBS), Roswell Park Memorial Institute (St. Louis, MO, USA); (RPMI) 1640,
IMDM, M-199, 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES), YI-S, Adult Bovine
Serum (ABS), Gentamycin, Penicillin-Streptomycin-L-Glutamine (PSG), Artesunate, Alamar dye,
Dimethyl sulfoxide (DMSO), Sodium citrate, Adenine, Sodium bicarbonate (NaHCO3), AlbuMax
II, Sodium chloride (NaCl), Potassium chloride (KCl), Sodium Phosphate Dibasic (Na2HPO4),
Sodium Phosphate Monobasic (KH2PO4), and Sodium hydroxide (NaOH), were purchased from
Sigma-Aldrich, USA. All other chemicals and reagents were of analytical grade.
3.6. Compound Preparation for Bioassay
A stock solution of compound 1 was prepared at a concentration of 100 mM. This was achieved
by drying the compound with nitrogen gas and weighing on a balance (AND GH-120, A and D
Company Limited, Tokyo, JAPAN) to ascertain the mass of compound. Compound 1 was dissolved in
an appropriate amount of DMSO to attain the desired concentration. The stock solution was vortexed
(MSI Minishaker. IKA Company, Osaka, JAPAN) and filter sterilized into a vial through 0.45 µm
millipore filters under sterile conditions and stored at −20 ◦C until use.
3.7. Cell Culture
Erythrocytes were obtained from the blood of consenting volunteers (Blood group O+). Venous
blood was drawn into containers with citrate phosphate dextrose (CPD) solution and kept at 4 ◦C
overnight. This preparation was centrifuged at 2000 rpm for 10 min to separate the serum and buffy
coat (KUBOTA 5200 Centrifuge, Kubota Corporation, Osaka, JAPAN). Packed erythrocytes were
washed three times with parasite washing medium (RPMI 1640, buffered with, 50 µg/mL gentamicin
and 2 mM L-glutamine). Each washing step was carried out by the addition of wash medium, pipetting
up and down thrice, centrifuging at 2000 rpm for 10 min, and discarding the suspended medium.
After washing, wash medium was added to the packed erythrocytes and stored at 4 ◦C until ready
to use. Washed red blood cells were stored and used for up to two weeks maximum, after which new
blood was collected. Erythrocytic stages of the malaria parasite (Plasmodium falciparum-chloroquine
sensitive strain 3D7) were cultured in 25 mL flasks using the method of Trager and Jensen (1976),
with modifications. Erythrocytes were maintained at 2% haematocrit (v/v) cell suspension in complete
malaria parasite medium (RPMI 1640, buffered with 25 mM HEPES, supplemented with 7.5% NaHCO3,
25 ug/mL gentamycin, 5% heat-inactivated human O+ serum; from consenting subjects) and 5 mg/mL
AlbuMax II, and incubated at 37 ◦C under gas conditions of 2% O2, 5% CO2, and 93% N2. Parasite
growth and development were monitored with a Giemsa stained thin blood smear. Parasite culture
was purified by using 5% sorbitol to obtain matured erythrocyte parasitic stages (late trophozoites and
schizonts) from uninfected cells. The matured erythrocyte parasitic stages (purity > 90%) obtained
were used to screen the compound for antimalarial activity.
The GUTat 3.1 strain of the bloodstream form of T. brucei parasites was used in this study.
Parasites were cultured in vitro according to the conditions established previously by Yabu et al. in
1998 [31]. Parasites were used when they reached a confluent concentration of 1 × 106 parasites/mL.
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Estimation of parasitemia was done with the Neubauer counting chamber. Parasites were diluted to
a concentration of 3 × 105 parasites/mL with IMDM medium and used for the drug assay.
The log-phase promastigotes of L. donovani (D10) and L. major (NR48815) were cultured in M-119
growth medium with a working concentration of 6 × 106 cells/mL. Parasites were used when they
reached a confluent concentration of 1 × 106 parasite/mL. Estimation of parasitemia was done with
the Neubauer counting chamber. Parasites were diluted to a concentration of 3 × 105 parasites/mL
with M199 medium and used for the drug assay.
3.8. Preparation of Cercarial Suspension
Schistosome cercariae were obtained from experimentally infected Biomphalaria pfeifferi snails.
Briefly, five laboratory four week-infected snails known to be shedding cercariae were placed in a test
tube containing 2 mL of distilled water and allowed to shed cercariae by exposing them to artificial
light at 28 ± 1 ◦C for 2 h. The number of cercariae in 50 µL was counted microscopically in triplicate
samples and the average count used for anticercariae evaluation was 20 cercariae per well.
3.9. Bio-Assays
3.9.1. Screening for Anti-Malaria Activity Using the SYBR Green I Assay
Screening for antimalarial activity was achieved using the SYBR Green I fluorescence assay as
described by Smilktein et al. in 2004 [32,33], with some modifications. Serial dilutions of the standard
(artesunate) which served as an experimental control and stock solutions of compounds to yield
final concentrations ranging from 15.63 nM to 500 nM and 1.95 µg/mL to 250 µg/mL, respectively,
were prepared. The matured erythrocyte parasitic stages were treated with the compound and
washed erythrocytes in 96-well plates and incubated with complete malaria parasite medium until
harvested after 48 h. Slides were prepared and percent parasitaemia was determined by counting the
number of infected cells in a total of 500 erythrocytes, in the Giemsa-stained thin blood smear. Briefly,
an aliquot of 5 µL per concentration of the standard drug and compound was dispensed into test
wells. About 95 µL of complete malaria parasite medium with washed erythrocytes at 2% haematocrit
and the purified matured erythrocyte parasitic stages (1% parasitaemia) was added, and incubated
at 37 ◦C under gaseous conditions as stated above, while untreated erythrocytes were used as the
control. Wells containing erythrocytes at 2% haematocrit, infected erythrocytes at 2% haematocrit,
and complete parasite medium alone served as negative controls, positive controls, and blank controls,
respectively. Furthermore, wells containing infected parasites and 0.1% DMSO served as reference
controls. The final volume per well was 100 µL. Plates were then incubated for 24 h as described
above in the cultivation of malaria parasites. About a 100 µL aliquot of 2.5× buffered SYBR Green I
(0.25 µL of SYBR Green I/mL of phosphate buffer saline) was added to each well after incubation.
3.9.2. In Vitro Viability Test for Trypanosome Parasites
The Alamar Blue assay was carried out on treated and untreated trypanosome parasites to
ascertain their viability. The assay was performed in a 96-well plate following the manufacturer’s
instructions, with modification. Briefly, 1.5 × 104 parasites were seeded with varied concentrations of
the compound ranging from 0 µM to 100 µM. Final concentrations of DMSO were kept at 0.1%. After the
incubation of parasites with or without the compound for 24 h at 37 ◦C in 5% CO2, 10% Alamar Blue
dye was added, and the parasites were incubated another 24 h in darkness. After a total of 48 h, the plate
was read for absorbance at 540 nm using the Tecan Sunrise Wako spectrophotometer, AUSTRIA GmbH.
The trend curve was drawn to obtain a 50% inhibitory concentration (IC50) for the compound.
3.9.3. In Vitro Viability Test for Leishmania Parasites
The Alamar Blue assay was carried out on treated and untreated leishmania parasites to ascertain
their viability. The assay was performed in a 96-well plate following the manufacturer’s instructions,
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with modification. About 3 × 105 parasites were seeded with varied concentrations of the compound
ranging from 0 µM to 100 µM. Final concentrations of DMSO were kept at 0.1%. After incubation of
parasites with or without the compound for 24 h at 28 ◦C, 10% Alamar Blue dye was added, and the
parasites were incubated for another 24 h in darkness. After a total of 48 h, the plate was read for
absorbance at 540 nm using the Tecan Sunrise Wako spectrophotometer, AUSTRIA GmbH (Salzburg,
Austria). The trend curve was drawn to obtain a 50% inhibitory concentration (IC50) for the compound.
3.9.4. In Vitro Cercariacidal Activity Test
Varied concentrations of the compound ranging from 0 µM to 100 µM were freshly prepared in
a 24-microtiter well plate (Costar) and analyzed alongside the positive control (artesunate 10 µM).
An average number of 20 freshly shed cercariae were transferred into each well plate (Costar) with
a micropipette. The same number of cercariae were placed in a well containing 0.1% DMSO as the
negative control. All experiments were carried out in duplicate and repeated. Mobility and viability
of the Schistosoma infectious stage (cercariae) were observed for 2 h 30 min at 30 min intervals
since infectivity of cercariae is known to be rapidly lost after 12 h [34,35]. Unaffected free swimming
larvae, immobile, and dead cercariae at the bottom of the wells were observed at 4× magnification
with an inverted microscope (Olympus CK 300, OLYMPUS, Tokyo, Japan). Survival and mortality at
a successive interval of 15, 30, 60, 90, 120, and 150 min were recorded. Cercariae were presumed dead
when they stopped moving and sank down to the bottom of the well with their tails detached [35].
The LC50 values of the compound on schistosome cercariae were determined at 1 and 2 h. The minimal
lethal concentration (MLC), which is the minimum concentration needed to kill all cercariae, and the
minimal effective concentration (MEC), which is the minimum concentration needed to observe any
change in viability or morphology of cercariae, were determined after 2 h.
3.9.5. In-Vitro Susceptibility Testing of Trichomonas Mobilensis
Compound 1 was prepared at a concentration of 0–100 µM in 96-well plates. Trophozoites of
Trichomonas mobilensis were seeded in the well plates at a concentration of 2 × 106 cells/mL. The plates
were sealed with seal stickers to provide anaerobic conditions for parasites and transferred into
an Anaero Pack jar with gas generators. The jar was incubated at 28 ◦C for 48 h. Parasites were
transferred into black well plates and 100 µL ATP bioluminescent was added before incubating for
20 min, followed by luminescence readings using the GloMAX multidetection system (Promega Corp.,
Madison, WI, USA).
4. Conclusions
The imidazole ring is an important, very common functionality present in many potent bioactive
natural and synthetic molecules and drugs. When an imidazole moiety is introduced into a compound,
it modulates the physicochemical properties of the compound. The physical and chemical properties
of the imidazole ring make it well-suited for weak to strong binding to a variety of enzymes and
receptors, resulting in a broad spectrum of activities. Consequently, imidazole-based compounds
have been found to possess anticancer, antifungal, antibacterial, antitubercular, anti-inflammatory,
antineuropathic, antihypertensive, antihistaminic, antiobesity, antiviral, and antiparasitic activities [36].
Megazol, benznidazole, and metronidazole are well-known examples of potent imidazole-based
antiparasitics [36]. Countless bioactive microbial peptides like bacitracin and gassericin contain the
imidazole moiety due to the incorporation of the amino acid histidine, but molecules like urocanic acid,
leuhistin, and tricladins A and B show the potential for further imidazole metabolism by microbes.
The interesting antiparasitic activity shown by paenidigyamycin A in this project is therefore not
surprising and offers an opportunity for further development of this pharmacophore.
Supplementary Materials: The following are available online at http://www.mdpi.com/1660-3397/17/1/9/s1,
Raw 1D- and 2D-NMR spectra of compound 1 are provided in Figures S6–S12. Figure S13, Modified Kupchan
solvent partitioning of the crude extract of Paenibacillus sp. DE2SH gives FH, FD, FM and WB fractions.
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Figure S14, Sephadex LH-20 Chromatography of FM fraction followed by Semi-preparative HPLC gives pure
Paenidigyamycin A (1). Figure S15, Schematic representation of a feasible fragmentation pathway for possible
Paenidigyamycin A (1) analogue under HRESI-LC-MS-MS conditions. Figure S16, HRESI-LC-MS shows the
possible presence of a Paenidigyamycin A (1) analogue. Figure S17, HPLC Chromatogram of Paenidigyamycin A
(1) with UV profile.
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